Paul L. Berns - 08 Jan 2026 Form 4 Insider Report for Neumora Therapeutics, Inc. (NMRA)

Role: Title: Chief Executive Officer and Chairman of the Board, Director
Signature: /s/ Michael Milligan, as Attorney-in-Fact for Paul L. Berns
Issuer symbol: NMRA
Transactions as of: 08 Jan 2026
Net transactions value: $0
Form type: 4
Filing time: 09 Jan 2026, 16:17:54 UTC
Previous filing: 13 Nov 2025
Next filing: 19 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
BERNS PAUL L	Title: Chief Executive Officer and Chairman of the Board, Director	C/O NEUMORA THERAPEUTICS, INC., 260 ARSENAL WAY, SUITE 1, WATERTOWN	/s/ Michael Milligan, as Attorney-in-Fact for Paul L. Berns	09 Jan 2026	0001202769

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NMRA	Stock Option (Right to Buy)	Award	$0	+1,650,000		$0.000000	1,650,000	08 Jan 2026	Common Stock	1,650,000	$2.33	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	25% of the shares subject to the option vest on the first anniversary measured from January 8, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

Remarks:

Title: Chief Executive Officer and Chairman of the Board